| 2003-2007年中国恶性淋巴瘤发病与死亡分析 |
| |
| 引用本文： | 徐原林, 王华庆, 钱正子, 周世勇, 张会来, 邱立华, 王先火, 刘贤明, 王平. 非霍奇金淋巴瘤继发第二肿瘤54例临床分析[J]. 中国肿瘤临床, 2012, 39(19): 1426-1429+1433. DOI: 10.3969/j.issn.1000-8179.2012.19.009 |
| |
| 作者姓名： | 徐原林 王华庆 钱正子 周世勇 张会来 邱立华 王先火 刘贤明 王平 |
| |
| 作者单位： | 天津医科大学附属肿瘤医院淋巴肿瘤科 中美淋巴血液肿瘤诊治中心, 天津市肿瘤防治重点实验室（天津市300060） |
| |
| 摘 要： | 目的 探讨非霍奇金淋巴瘤(NHL)患者继发第二肿瘤的临床特点、风险评估及预后分析。 方法 收集我院2000~2010年间1 839例NHL患者临床资料, 从中检索继发第二肿瘤的病例并分析继发肿瘤的相关风险及预后因素。 结果 54例NHL患者在治疗后1~10年发生了第二种肿瘤, 其中白血病19例, 肺癌9例, 结直肠癌9例, 乳腺癌3例。多因素分析显示, 初治年龄大于45岁的NHL患者发生各种继发肿瘤的风险更高。8周期以上的化疗仅增加白血病发生的风险、NHL的AnnArbor分期是继发肿瘤患者的独立预后因素, 同时与继发第二肿瘤的潜伏时间相关。 结论 初治年龄大于45岁以及接受8周期以上的化疗是继发肿瘤的危险因素。AnnArbor分期较晚的NHL继发肿瘤潜伏时间和生存时间均较短。
|
| 关 键 词： | 非霍奇金淋巴瘤 继发第二肿瘤 风险 预后因素 |
| 收稿时间： | 2012-07-25 |
| 修稿时间： | 2012-09-11 |
Monoclonal Antibody Therapy and Non-Hodgkin's Lymphoma |
| |
| Yuanlin XU, Huaqing WANG, Zhengzi QIAN, Shiyong ZHOU, Huilai ZHANG, Lihua QIU, Xianhuo WANG, Xianming LIU, Ping WANG. Clinical Analysis of Non-Hodgkin's Lymphoma Associated with Secondary Malignant Neoplasm[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(19): 1426-1429+1433. DOI: 10.3969/j.issn.1000-8179.2012.19.009 |
| |
| Authors: | Yuanlin XU Huaqing WANG Zhengzi QIAN Shiyong ZHOU Huilai ZHANG Lihua QIU Xianhuo WANG Xianming LIU Ping WANG |
| |
| Affiliation: | Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Sino-US Center for Lymphoma and Leukemia City, Key Laboratory of Cancer Prevention and Treatment of Tianjin city, Tianjin 300060, China |
| |
| Abstract: | Objective To understand the clinical characteristics and prognostic factors of patients with secondary malignant neoplasm (SMN) following Non-Hodgkin's lymphoma(NHL). Methods Clinical data of patients with SMN after they were treated for NHL in our department from 2001 to 2010 were collected and analyzed. Results Fifty-four SMN cases(35 males and 19 females) were observed.Multivariate regression analyses showed that patients > 45 years old had higher risk of secondary cancer.Those who received more than eight cycles of chemotherapy had increased risk of leukemia.The Ann Arbor stage of NHL is not only an independent prognostic factor of SMN, but it also has significant independent impacts on the time independence of secondary tumors. Conclusion The recognition of SMN should be enhanced, and the screening for it in a high-risk population should be performed.The overuse of therapy to improve the patient's condition should also be avoided. |
| |
| Keywords: | Non-Hodgkin's lymphoma Secondary malignant neoplasm Risk factor Prognostic factor |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
